Issue 2/2021
Content (14 Articles)
Tumor microenvironment promotes breast cancer chemoresistance
Umar Mehraj, Abid Hamid Dar, Nissar A. Wani, Manzoor A. Mir
Disulfiram: a novel repurposed drug for cancer therapy
Chen Lu, Xinyan Li, Yongya Ren, Xiao Zhang
Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid
Milene Volpato, Nicola Ingram, Sarah L Perry, Jade Spencer, Amanda D Race, Catriona Marshall, John M Hutchinson, Anna Nicolaou, Paul M Loadman, P Louise Coletta, Mark A Hull
Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types
Nadia Terranova, Mendel Jansen, Martin Falk, Bart S. Hendriks
Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors
Timothy Crook, Andrew Gaya, Raymond Page, Sewanti Limaye, Anantbhushan Ranade, Amit Bhatt, Sanket Patil, Prashant Kumar, Darshana Patil, Dadasaheb Akolkar
PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1
Shuo Yu, Yang Li, Hui Ren, Hong Zhou, Qian Ning, Xue Chen, Tinghua Hu, Lan Yang
Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma
Haofeng Lu, Lin Zhou, Hongping Zuo, Wenjin Le, Jianfei Hu, Tiequan Zhang, Mi Li, Yufeng Yuan
Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients
Nastja Lunar, Marie-Christine Etienne-Grimaldi, Pauline Macaire, Fabienne Thomas, Florence Dalenc, Jean-Marc Ferrero, Xavier Pivot, Gérard Milano, Bernard Royer, Antonin Schmitt
Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers
Naveed Shaik, Robert R. LaBadie, Brian Hee, Geoffrey Chan
Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer
Akira Yamagata, Toshihide Yokoyama, Yasushi Fukuda, Tadashi Ishida
Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1–XPF-mediated DNA repair
Gloria Ciniero, Ahmed H. Elmenoufy, Francesco Gentile, Michael Weinfeld, Marco A. Deriu, Frederick G. West, Jack A. Tuszynski, Charles Dumontet, Emeline Cros-Perrial, Lars Petter Jordheim
Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors
R. B. Verheijen, T. T. van Duijl, M. M. van den Heuvel, D. Vessies, M. Muller, J. H. Beijnen, J. M. Janssen, J. H. M. Schellens, N. Steeghs, D. van den Broek, A. D. R. Huitema
Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(−) breast cancer receiving salvage treatment with everolimus/exemestane
Maria Spiliotaki, Galatea Kallergi, Christos Nikolaou, Nikolaos Xenidis, Eleni Politaki, Stella Apostolaki, Nefeli Georgoulia, Filippos Koinis, Nikolaos Tsoukalas, Dora Hatzidaki, Athanasios Kotsakis, Vassilis Georgoulias
Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review
Malvi Savani, Katti Woerner, Lihong Bu, Mark Birkenbach, Keith M. Skubitz